Get the Stockscreener App
133.96
3.26%
-4.52
After Hours:
133.96
Icon Plc stock is traded at $133.96, with a volume of 1.18M.
It is down -3.26% in the last 24 hours and down -13.85% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$138.48
Open:
$138.87
24h Volume:
1.18M
Relative Volume:
0.88
Market Cap:
$11.36B
Revenue:
$8.31B
Net Income/Loss:
$747.89M
P/E Ratio:
14.93
EPS:
8.97
Net Cash Flow:
$1.23B
1W Performance:
-6.30%
1M Performance:
-13.85%
6M Performance:
-37.67%
1Y Performance:
-57.48%
1-Day Range:
$133.86
$140.05
1-Week Range:
$133.86
$145.00
52-Week Range:
$133.28
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
133.96 | 11.36B | 8.31B | 747.89M | 1.23B | 8.97 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Daily Progress: Icon Plc (ICLR) Drop -5.54, Closing at 135.10 - DWinneX
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies | ICLR Stock News - GuruFocus
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies - Business Wire
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR S - GuruFocus
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR Stock News - GuruFocus
ICON plc (ICLR) Consensus: A 29% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Icon Plc Earnings Call: Navigating Challenges and Opportunities - TipRanks
Icon (ICLR) Sees Price Target Adjustment by Barclays | ICLR Stock News - GuruFocus
ICON plc Expands Share Buyback Program Amid Vaccine Study Delays and Tariff Uncertainty - TipRanks
Icon Plc [ICLR] Officer makes an insider purchase of 1,540 shares worth 0.29 million. - knoxdaily.com
Market Analysts see Icon Plc [ICLR] gaining to $150. Time to buy? - dbtnews.com
Icon (ICLR) Price Target Reduced by BofA Analyst | ICLR Stock Ne - GuruFocus
ICLR Faces Revenue Pressure Amid Elevated Cancellations - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Out - GuruFocus
Icon PLC (ICLR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - Yahoo Finance
ICON plc Reports Q1 2025 Financial Results - TipRanks
Icon Earnings: Macroeconomic Issues and Trial Delays Affect Our Near-Term View - Morningstar
Narrow-Moat Icon Faces Macroeconomic Issues and Trial Delays That Constrain Its Near-Term Outlook - Morningstar
The Future of Icon Plc: Analyzing ICLR - investchronicle.com
A look at ICLR’s current quarter earnings estimates - uspostnews.com
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down - Yahoo Finance
Icon PLC: Q1 Earnings Snapshot - MySA
ICON PLC earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Icon PLC (ICLR) Beats Q1 Earnings Estimates - Yahoo Finance
ICON PLC reports results for the quarter ended March 31Earnings Summary - TradingView
ICON PLC earnings beat, revenue fell short of estimates - Investing.com
ICON plc Reports Q1 2025 Financial Results Amid Market Challenges - TipRanks
ICON Reports First Quarter 2025 Results | ICLR Stock News - GuruFocus
Earnings Flash (ICLR) ICON PLC Reports Q1 Adjusted EPS $3.19, vs. FactSet Est of $3.10 - marketscreener.com
Earnings Flash (ICLR) ICON PLC Posts Q1 Revenue $2B, vs. FactSet Est of $2.01B - marketscreener.com
ICON Reports First Quarter 2025 Results - Business Wire
Icon Plc (NASDAQ: ICLR) Shares Are Down -29.22% Year To Date. - Marketing Sentinel
Checking in on Icon Plc (ICLR) after recent insiders movement - knoxdaily.com
Icon (ICLR) Downgraded by JPMorgan Amid Uncertain Market Conditi - GuruFocus
Icon (ICLR) Downgraded by JPMorgan Amid Uncertain Market Conditions | ICLR Stock News - GuruFocus
ICON plc (ICLR) Stock Analysis: Uncovering a 44.70% Potential Upside in Healthcare Research - DirectorsTalk Interviews
ICLR Stock Sees Surge of Approximately 1.66% in Last Five Days - knoxdaily.com
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for - MSN
Icon PLC (ICLR) Stock Price Up 4.72% on Apr 23 - GuruFocus
Recent Insider Activity Could Benefit Icon Plc (ICLR) - knoxdaily.com
Icon Plc (ICLR)’s Day in Review: Closing at 137.23, Down by -1.50 - DWinneX
ICON plc (ICLR): A Deep Value Play with 53% Upside Potential - DirectorsTalk Interviews
ICON Plc stock hits 52-week low at $138.47 amid market challenges - Investing.com Canada
ICON Plc stock hits 52-week low at $138.47 amid market challenges By Investing.com - Investing.com South Africa
Clinical Trial Investigative Site Network Market Top Companies - openPR.com
Clinical trials giant Icon accused of ‘scheme to deceive market’ in new US class action - The Irish Independent
TD Cowen Downgrades Icon (ICLR) Amid Concerns Over Future Growth - GuruFocus
ICON plc (ICLR) Stock: A 54.73% Potential Upside That Investors Can’t Ignore - DirectorsTalk Interviews
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ICON - StreetInsider
ICLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FINAL REMINDER ICLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts ICON PLC Investors to Participate in the Class Action Lawsuit - markets.businessinsider.com
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):